Open-label pitolisant + Double-blind placebo + Double-blind pitolisant
Phase 3Completed 2 views this week 0 watching💤 Quiet
Interest: 34/100
34
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Idiopathic Hypersomnia
Conditions
Idiopathic Hypersomnia
Trial Timeline
May 25, 2022 → Sep 8, 2023
NCT ID
NCT05156047About Open-label pitolisant + Double-blind placebo + Double-blind pitolisant
Open-label pitolisant + Double-blind placebo + Double-blind pitolisant is a phase 3 stage product being developed by Harmony Biosciences for Idiopathic Hypersomnia. The current trial status is completed. This product is registered under clinical trial identifier NCT05156047. Target conditions include Idiopathic Hypersomnia.
What happened to similar drugs?
20 of 20 similar drugs in Idiopathic Hypersomnia were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05156047 | Phase 3 | Completed |
Competing Products
20 competing products in Idiopathic Hypersomnia